Sapropterin for phenylketonuria (all ages)

Document first published:: 4 November 2020
Page updated:: 17 December 2021
Topic:: Specialised commissioning
Publication type:: Guidance, Policy or strategy

Sapropterin is recommended to be available as a treatment option through routine commissioning for phenylketonuria

Document

Commissioning position on sapropterin for the treatment of phenylketonuria (pku) and tetrahydrobiopterin (bh4) disorders

Commissioning position on sapropterin for the treatment of phenylketonuria (pku) and tetrahydrobiopterin (bh4) disorders

PDF
107 KB
3 pages

Summary

Updated in December 2021.

Document

Consultation Report

Consultation Report

PDF
103 KB
8 pages

Document

Equality and Health Inequalities Impact Assessment

Equality and Health Inequalities Impact Assessment

PDF
138 KB
15 pages

Document

Evidence Review

Evidence Review

PDF
355 KB
37 pages

Document

Clinical Panel Report

Clinical Panel Report

PDF
65 KB
3 pages

Document

CPAG Summary Report

CPAG Summary Report

PDF
88 KB
7 pages